Squawk on the Street FDA Approves Novo Nordisk's Wegovy Pill, ServiceNow CEO on $7.75B Deal, Q3 GDP Jumps 12/23/25
12 snips
Dec 23, 2025 
Bill McDermott, CEO of ServiceNow, chats about his company's bold $7.75 billion acquisition of cybersecurity firm Armis. He highlights how this move enhances visibility across IT and IoT, bolstering ServiceNow's growth. The conversation also dives into the implications of the latest FDA approval for Novo Nordisk's Wegovy pill, and how it's reshaping the obesity treatment landscape. McDermott further discusses industry headwinds and the importance of partnerships with tech giants like Microsoft and Google.
AI Snips
Chapters
Transcript
Episode notes
Oral GLP-1 Could Reshape Weight-Loss Market
- Novo Nordisk's Wegovy pill is the first oral GLP-1 FDA-approved for obesity and will likely change patient preference versus weekly shots.
- Jim Cramer and Carl Quintanilla emphasize ease of use, storage and adherence advantages that may shift market share.
GLP-1s Ripple Through Consumer Industries
- Analysts highlight industry impacts beyond pharma, like alcohol and hospitality, from broader GLP-1 adoption.
- Jim Cramer warns of existential shifts in consumer behavior affecting brands like Jim Beam and restaurants.
ServiceNow Expands Security Footprint
- ServiceNow is acquiring Armis for $7.75 billion to add deep cybersecurity and asset visibility to its platform.
- Bill McDermott frames the deal as expanding ServiceNow's control tower across IT, OT and IoT environments.